Background--The regenerative potential of cardiosphere-derived cells (CDCs) for ischemic heart disease has been demonstrated in mice, rats, pigs, and a recently completed clinical trial (CADUCEUS). CDCs are CD105 + stromal cells of intrinsic cardiac origin, but the antigenic characteristics of the active fraction remain to be defined. CDCs contain a small minority of c-kit + cells, which have been argued to be cardiac progenitors, and a variable fraction of CD90 + cells whose bioactivity is unclear.
Methods--We performed a retrospective analysis of data from the CADUCEUS trial and a prospective mouse study to elucidate the roles of c-kit + and CD90 + cells in human CDCs. Here, we show, surprisingly, that c-kit expression has no relationship to CDCs' therapeutic efficacy in humans, and depletion of c-kit + cells does not undermine the structural and functional benefits of CDCs in a mouse model of myocardial infarction (MI). In contrast, CD90 expression negatively correlates with the therapeutic benefit of CDCs in humans (ie, higher CD90 expression associated with lower efficacy). Depletion of CD90 + cells augments the functional potency of CDCs in murine MI. CD90
À CDCs secrete lower levels of inflammatory cytokines and can differentiate into cardiomyocytes in vitro and in vivo.
Conclusion--The majority population of CDCs (CD105 + /CD90
À /c-kit À ) constitutes the active fraction, both in terms of therapeutic efficacy and in the ability to undergo cardiomyogenic differentiation. The c-kit + fraction is neither necessary for, nor contributory to, the regenerative efficacy of CDCs. ( J Am Heart Assoc. 2014;3:e001260 doi: 10.1161/JAHA.114.001260) Key Words: cardiosphere-derived cells • CD90 • ckit • myocardial infarction N umerous animal studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] and the first-in-human 11, 12 have demonstrated the regenerative potential of cardiosphere-derived cells (CDCs) in ischemic cardiomyopathy. CDCs are intrinsic to the heart 13 and uniformly express the transforming growth factor beta receptor accessory subunit, CD105 (endoglin), but are negative for the pan-hematopoietic marker, CD45. 7, 10 CDCs contain a small fraction of CD117 (c-kit)-positive cells, argued to be cardiac stem cells, 14, 15 and a variable fraction of CD90
CADUCEUS trial
(Thy-1)-positive cells, which have not been characterized, but may represent a mesenchymal subfraction. 16 Thus, the majority population is negative for both CD90 and c-kit, but the active principle is, as yet, undefined. 
Methods

Derivation and Characterization of Human CDCs
Institutional review board (IRB) approval was obtained for all procedures. Human CDCs were generated and expanded, as previously described, from myocardial specimens. 10 Human Scar Size Data IRB approval was obtained for all procedures, and all study subjects gave informed consent. Scar size, defined as scar mass divided by total left ventricular (LV) mass, was quantified by contrast-enhanced cardiac magnetic resonance imaging (MRI), as previously described. 11, 12 Changes in scar size from baseline study to the 12-month follow-up study were quantified in each patient and correlated with the c-kit + and CD90 + percentages in each corresponding autologous CDC preparation.
Mouse MI Model and Cell Injection
All animal studies were performed in an American Association for Accreditation of Laboratory Animal Care-accredited facility with approval from the institutional animal care and use committee of the Cedars-Sinai Health System. Acute MI was created in male severe combined immunodeficiency (SCID)-beige mice (10 to 12 weeks old), as previously described. 7, 10 Briefly, immediately after ligation of the left anterior descending artery with 9-0 prolene, hearts were injected at 4 points in the infarct border zone with a total of 
Cardiac Function Assessment
Mice underwent echocardiography 4 hours (baseline) and 3 weeks post-MI using a Vevo 770
TM
Imaging System (VisualSonics, Toronto, Ontario, Canada). 7, 10 Hearts were imaged 2D in long-axis views at the level of the greatest LV diameter. LV ejection fraction (LVEF) was measured with VisualSonics V1.3.8 software from views taken through the infarcted area. Studies were read and analyzed by an experienced echocardiographer who was blinded as to study-group identity.
Cardiomyocyte Cycling Assay
Neonatal rat cardiomyocytes (NRCMs) were derived as previously described 17, 18 and plated onto fibronectin-coated chamber slides, with or without CDCs at a 1:1 coculture ratio. 
Paracrine Assay
To compare the production of various growth factors and cytokines, CDCs were seeded in 6-well culture plates at densities of 1910 6 cells/mL in FBS-free IMDM media for 3 days. The supernatants (conditioned media) were collected and the concentrations of vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor, insulin-like growth factor 1, and stromal-derived factor 1 were measured with human-specific ELISA kits (R&D Systems), according to the manufacturer's instructions. Matrix metalloproteinase (MMP) activities of CDC-conditioned media were measured by the InnoZyme TM MMP-2/MMP-9 Activity Fluorogenic Assay kit (EMD Chemical Group, Temecula, CA). Secretion of various inflammatory cytokines was visualized by a semiquantitative Ab array (RayBiotech, Norcross, GA), and intensity was determined using ImageJ software (NIH).
Cardiac Differentiation Assay and Heart Histology
CDCs were cultured in cardiomyocyte differentiation media (Millipore, Billerica, MA), after which the cells were fixed with 4% PFA, blocked/permeabilized with protein block solution (Dako) containing 1% saponin (Sigma-Aldrich), and then stained with chicken anti-CD105 (Sigma-Aldrich) and mouse anti-aSA (Sigma-Aldrich). FITC or Texas Red secondary Abs were obtained from Abcam. For heart histology, all animals were sacrificed at 3 weeks (after echocardiography study) and excised hearts were cryosectioned (5-lm thickness). Heart cryosections were then fixed with 4% PFA, blocked/ permeabilized, and stained with mouse anti-human nuclear antigen (HNA; Millipore) and rabbit anti-aSA (Abcam). Images were taken with a confocal microscope. Detailed Ab information is included in Table S1 .
Statistical Analysis
Results are presented as meanAESD, unless specified otherwise. Comparisons between any 2 groups were performed using the 2-tailed unpaired Student t test. Comparisons among more than 2 groups were performed using 1-way ANOVA with post-hoc Bonferroni's correction. Differences were considered statistically significant when P<0.05. Correlation analysis was performed by linear regression using the GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA). Figure 1A ; range, 93.0% to 99.8%; meanAESD, 97.8AE1.7%) and are negative for CD45 ( Figure 1B ; range, 0.0% to 1.0%; meanAESD, 0.2AE0.4%). After the clinical trial was completed, we were able to examine 13 of the 17 patient-derived CDCs for c-kit and/or CD90 expression. (The other cell products had been completely infused, leaving no residual for banking.) Only a small fraction of the autologously infused human CDCs express c-kit, although the relative percentage varies greatly (>20-fold) from patient to patient ( Figure 1C ; range, 0.3% to 7.2%; meanAESD, 2.9AE2.0%). In contrast, CD90 expression ranges broadly (0.2% to 94.6%; Figure 1D ; meanAESD, 25.1AE26.9%). Scar size reduction, assessed by contrast cardiac MRI, was the major efficacy endpoint in the CADUCEUS trial. Linear regression analysis, performed in the 10 (of 17) patients' CDC lines for which all 3 relevant variables (c-kit expression, CD90 expression, and 12-month scar size data) were available, revealed that c-kit expression does not correlate with the scar-reducing ability of CDCs ( Figure 1E ; R 2 =0.006, P=0.83). However, CD90 expression negatively correlated with scar reduction ( Figure 1F ; R 2 =0.7863, P=0.0006 ; Table S2 ), that is, higher CD90 expression levels were associated with lower efficacy (less scar reduction). These results hint that c-kit + cells are not an important determinant of the therapeutic efficacy of CDCs, whereas CD90 + cells may undermine the overall benefit of CDC therapy.
Results
Generating c-Kit-and CD90-Depleted CDCs by MACS
We further tested the roles of c-kit + and CD90 + cells by performing selective depletion experiments using MACS (Figures 2A and S1 ). The efficiency of cell sorting was confirmed by fluorescent microscopy and FCM ( Figure 2B and 2C). The c-kit-and CD90-depleted CDCs are hereafter referred to as c-kit DEP and CD90 DEP CDCs. We also prepared CDCs depleted for both c-kit + and CD90 + fractions; these cells are abbreviated as Double DEP CDCs. The MACS process did not affect cell viability, as confirmed by trypan blue assay ( Figure 2D ), nor did it affect the expression of other cellsurface markers (eg, CD105 and CD45; Figure 2E ). Heart morphometry at 3 weeks showed severe LV chamber dilatation and infarct wall thinning in control hearts ( Figures 3A and S2) . In contrast, all the CDC-treated groups exhibited some degree of attenuated LV remodeling ( Figures 3A and S2 Figures 3B, 3C , and S2). These findings confirm the notion that CD90 À CDCs are superior to their CD90-containing counterparts in attenuating LV remodeling and preserving heart morphology in post-MI mice.
Depleting CD90 + Cells Enhances the Functional Benefit of CDCs
A consistent indicator of cell potency in this mouse model is the ability to produce functional benefit after transplantation. 1, 7, 10 LVEF values at baseline (ie, 4 hours post-MI) were comparable, indicating similar degrees of ischemic injury among groups ( Figure 3D ; Table S3 ). Over the following 3 weeks, LVEF deteriorated in the control group (white bar, Figure 3E ; Figure 3E ; Table S3 ). Taken together, these compound data sets show that depleting the c-kit + fraction from CDCs does not affect cardioprotective/ regenerative potency, whereas depleting the CD90 + fraction enhances the structural and functional benefits of CDC therapy. Consistent with the latter conclusion, in a separate set of studies using the same mouse MI model, we found that unsorted CDCs outperformed the CD90 + fraction in augmenting cardiac function at 3 weeks ( Figure S3 ).
Cardiomyocyte Proliferation and Apoptosis Assay
The in vivo therapeutic benefit of CDCs can be mimicked in vitro by coculturing neonatal rat cardiomyocytes with CDCs. 
Paracrine Factor and Cytokine Secretion
Paracrine mechanisms underlie the majority of the beneficial effects of CDC transplantation. 7, 8, 19 Consistent with our previous findings, CDCs secreted various growth factors ( Figure S6A through E) . Neither c-kit depletion nor CD90 depletion changed the production of these factors. Also, no differences in metalloproteinase activities (MMP2/ MMP9) were found among the 4 CDC groups ( Figure S6F ). On the other hand, inflammatory cytokine array analysis ( Figure S7A treatment and heart sections were stained for aSA and HNA (to identify engrafted cells; Figure 5D 
Discussion
The last decade witnessed a burst of cell therapy trials for ischemic cardiomyopathy. 20 The CADUCEUS trial 11 and the SCIPIO trial 15 have tested heart-derived cells in human beings. The first study used unsorted CDCs from endomyocardial biopsies and the second study used purified c-kit + cells cells). 25, 26 In humans, Thy-1 is also expressed by endothelial cells, smooth muscle cells, a subset of CD34 + bone marrow cells, fibroblasts, and fetal liver-derived hematopoietic cells. Strikingly, our results indicate that CD90 expression in CDCs undermines the functional benefit. In CADUCEUS, higher CD90 expression was associated with smaller therapeutic benefit ( Figure 1F ). Moreover, depleting the CD90 + fraction enhanced the functional benefit of CDCs in mice with MI ( Figure 3 ). These findings support the previous report that CDCs are functionally superior to MSCs in a mouse model of MI 7 : >99% of bone-marrow-derived MSCs and 85% of adipose-derived MSCs expressed CD90, whereas only 18% of CDCs did so in that particular study. We further confirmed that the CD90 + cell fraction of CDCs secretes more inflammatory cytokines than the CD90 À counterpart ( Figure S4 ).
Elevation of these inflammatory cytokines (eg, IL-1) may lead to cardiomyocyte death and cardiac dysfunction. 27 In any case, the overall benefit of CDCs is diminished by the presence of CD90 + cells. Our findings confirm and extend a recent report that CD90 À CDCs are not only the majority fraction, but also crucial for the benefits of CDCs. 28 Our study has several limitations. First, we did not include a CD90
+ CDC group for direct comparison of its functional benefit with that of the CD90 À subpopulation. However, we did confirm that unsorted CDCs are functionally superior to the CD90 + subpopulation of CDCs ( Figure S2 ). Second, our data in support of enhanced in vivo cardiac differentiation by CD90 DEP CDCs are limited in that we did not use confocal zstack imaging to confirm the location of HNA + nuclei, nor did we perform ex vivo analysis of enzymatically isolated cardiomyocytes. However, the absolute number of HNA + /aSA + cells is small and unlikely to explain the observed benefits of cell transplantation. Indeed, the overall differentiation rate in CDCs is marginal in both in vitro and in vivo experiments, consistent with the idea that the differential functional performance of the various groups may be dominated by indirect paracrine effects. 7 Another limitation of our study is that a CDC-specific positive marker has yet to be discovered. We have not found any markers unique to the CD90 À population that are not expressed on the CD90 + population (or vice versa). Studies are ongoing to profile the CD90 À CDCs using genomics approaches. Last, but not least, the lack of significance for some our data sets may be a result of low statistical power. Nevertheless, our results point to a crucial, indispensable role of the c-kit À /CD90 À population for the regenerative potential of CDCs. In almost all CDC isolates from different human donors, this is the majority cell population (Figure 2 ). 7, 10 Future therapeutic trials of CDCs may benefit from CD90 depletion to enhance efficacy or, in allogeneic applications, selection of master cell banks that are naturally low in CD90 expression. Further studies are needed to fully elucidate the mechanisms for the observed benefit from CD90 depletion.
